Page 21«..10..20212223..»

Archive for the ‘Cardiac Stem Cells’ Category

BioRestorative Therapies Signs License Agreement for Stem Cell Disc/Spine Procedure

JUPITER, Fla., Jan. 31, 2012 /PRNewswire/ — BioRestorative Therapies, Inc. (OTCQB: BRTX) (“BRT”) today announced that it has entered into a License Agreement with Regenerative Sciences, LLC (“RS”) with respect to certain stem cell-related technology and clinical treatment procedures developed by RS. The treatment is an advanced stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, or numbness and tingling in the legs or feet as a result of bulging and herniated discs.

To date, over 40 procedures have been performed on patients. It is a minimally invasive out-patient procedure, and objective MRI data and patient outcomes for this novel injection procedure show positive results with limited patient downtime. BRT intends to utilize the existing treatment and outcome data, as well as further research, to prepare for clinical trials in the United States.

Pursuant to the agreement, BRT will obtain an exclusive license to utilize or sub-license a certain medical device for the administration of specific cells and/or cell products to the precise locations within the damaged disc and/or spine (and other parts of the body, if applicable) and an exclusive license to utilize or sublicense a certain method for culturing cells for use in repairing damaged areas. The agreement contemplates a closing of the license grant in March 2012, subject to the fulfillment of certain conditions. 

Mark Weinreb, Chairman and CEO of BRT, said, “This possible alternative to back surgery represents a large market for BRT once it begins offering the procedure to patients who might be facing spinal fusions or back surgery (which often times is unsuccessful). By delivering a particular cell population using a proprietary medical device that inserts a specialized needle into the disc and injects cells for repair and re-population, BRT hopes to revolutionize how degenerative disc disease will be treated.” 

About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc.'s goal is to become a medical center of excellence using cell and tissue protocols, primarily involving a patient's own (autologous) adult stem cells (non-embryonic), allowing patients to undergo cellular-based treatments. In June 2011, the Company launched a technology that involves the use of a brown fat cell-based therapeutic/aesthetic program, known as the ThermoStem™ Program.  The ThermoStem™ Program will focus on treatments for obesity, weight loss, diabetes, hypertension, other metabolic disorders and cardiac deficiencies and will involve the study of stem cells, several genes, proteins and/or mechanisms that are related to these diseases and disorders.  As more and more cellular therapies become standard of care, the Company believes its strength will be its focus on the unity of medical and scientific explanations for clinical procedures and outcomes for future personal medical applications.  The Company also plans to offer and sell facial creams and products under the Stem Pearls™ brand.

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10, as amended, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:  Mark Weinreb, CEO, Tel: (561) 904-6070, Fax: (561) 429-5684

Read the rest here:
BioRestorative Therapies Signs License Agreement for Stem Cell Disc/Spine Procedure

Cytori Receives Approval From FDA to Initiate U.S. Cardiac Cell Therapy Trial; Investigational Device Exemption (IDE …

SOURCE: Cytori Therapeutics, Inc.

SAN DIEGO, CA–(Marketwire – Jan 30, 2012) – Cytori Therapeutics (NASDAQ: CYTX) has received an Investigational Device Exemption (IDE) approval from the U.S. FDA to begin the ATHENA trial. ATHENA will investigate the use of the Celution® System, an innovative medical device to prepare adipose-derived stem and regenerative cells (ADRCs) to treat a form of coronary heart disease, chronic myocardial ischemia (CMI). The IDE application was originally submitted to the FDA in December 2011.

ATHENA is a multi-center, randomized, double blind, placebo controlled, pilot trial to investigate the use of autologous, clinical-grade ADRCs, processed at the point-of-care with Cytori's proprietary Celution® System. The trial will enroll up to 45 patients with no-option CMI who have limited therapeutic options. It will evaluate a variety of clinical and functional outcomes, including safety, peak oxygen consumption (mVO2), and clinical outcomes at 12-months.

“Following our pre-IDE meeting with the FDA, we received constructive guidance and implemented the Agency's recommendations, ultimately resulting in rapid approval to initiate the ATHENA trial,” said Christopher J. Calhoun, chief executive officer for Cytori. “We look forward to working with the FDA on further defining our clinical strategy in the U.S.”

Previously, Cytori reported six and 18-month trial data from PRECISE, a European clinical trial for this same indication showing improvement in mVO2. In Europe, Cytori has applied to expand its Celution® System CE Mark to include no-option CMI claims based on data from the PRECISE trial. Cytori is also enrolling ADVANCE, a European pivotal trial investigating the Celution® System for acute myocardial infarction (heart attacks).

In the U.S., it is estimated that 120,000 to 250,000 patients are diagnosed each year with chronic myocardial ischemia, a subset of the approximate 5.8 million patients who currently have some form of heart failure. CMI patients typically have undergone multiple revascularization procedures that have not improved their condition and are at a stage where they have few therapeutic options remaining.

About Cytori
Cytori is a leader in providing patients and physicians around the world with medical technologies that harness the potential of adult regenerative cells from adipose tissue. The Celution® System family of medical devices and instruments is being sold into the European and Asian cosmetic and reconstructive surgery markets and available in the United States only for use as an investigational device under Cytori's FDA approved IDE. Our StemSource® product line is sold globally for cell banking and research applications. Our PureGraft® products are available in North America and Europe for fat grafting procedures. http://www.cytori.com

Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position, such as the successful initiation of a clinical trial of the Company's Celution® System for chronic myocardial ischemia, our efforts to expand our CE Mark. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks include clinical and regulatory uncertainties, such as those associated with the ATHENA clinical trial, including risks in the collection and results of clinical data, final clinical outcomes, dependence on third party performance, and other risks and uncertainties described under the “Risk Factors” in Cytori's Securities and Exchange Commission Filings. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

Go here to see the original:
Cytori Receives Approval From FDA to Initiate U.S. Cardiac Cell Therapy Trial; Investigational Device Exemption (IDE …

Scientists use silk from the tasar silkworm as a scaffold for heart tissue

Of all the body’s organs, the human heart is probably the one most primed for
performance and efficiency. Decade after decade, it continues
to pump blood around our bodies. However, this performance
optimisation comes at a high price: over the course of
evolution, almost all of the body’s own regeneration mechanisms
in the heart have become deactivated. As a result, a heart
attack is a very serious event for patients; dead cardiac cells
are irretrievably lost. The consequence of this is a permanent
deterioration in the heart’s pumping power and in the patient’s
quality of life.

In their attempt to develop a treatment for the repair of
cardiac tissue, scientists are pursuing the
aim of growing replacement tissue in the laboratory, which
could then be used to produce replacement patches for the
repair of damaged cardiac muscle. The reconstruction of a
three-dimensional structure poses a challenge here. Experiments
have already been carried out with many different materials
that could provide a scaffold substance for the loading of cardiac muscle cells.

“Whether natural or artificial in origin, all of the tested
fibres had serious disadvantages,” says Felix Engel, Research
Group Leader at the Max Planck Institute for Heart and Lung
Research in Bad Nauheim. “They were either too brittle, were
attacked by the immune system or did not enable the heart
muscle cells to adhere correctly to the fibres.” However, the
scientists have now found a possible solution in Kharagpur,
India.

At the university there, coin-sized disks are being produced
from the cocoon of the tasar silkworm (Antheraea mylitta). According to
Chinmoy Patra, an Indian scientist who now works in Engel’s
laboratory, the fibre produced by the tasar silkworm displays
several advantages over the other substances tested. “The
surface has protein structures that facilitate the adhesion of
heart muscle cells. It’s also coarser than other silk fibres.”
This is the reason why the muscle cells grow well on it and can
form a three-dimensional tissue structure. “The communication
between the cells was intact and they beat synchronously over a
period of 20 days, just like real heart muscle,” says Engel.

Despite these promising results, clinical application of the
fibre is not currently on the agenda. “Unlike in our study,
which we carried out using rat cells, the problem of obtaining
sufficient human cardiac cells as starting material has not yet
been solved,” says Engel. It is thought that the patient’s own
stem cells could be used as starting material to avoid
triggering an immune reaction. However, exactly how the
conversion of the stem cells into cardiac muscle cells works
remains a mystery.

More information: Chinmoy Patra, Sarmistha Talukdar,
Tatyana Novoyatleva, Siva R. Velagala, Christian Mühlfeld,
Banani Kundu, Subhas C. Kundu, Felix B. Engel
Silk protein fibroin from Antheraea mylitta for cardiac tissue
engineering, Biomaterials, Advance Online Publication
Januar 10, 2012

Provided by Max-Planck-Gesellschaft (news : web)

Continue reading here:
Scientists use silk from the tasar silkworm as a scaffold for heart tissue

Stem Cell Treatment for Heart Failure – Video


06-10-2011 17:25 A doctor becomes patient and gives his testimony on stem cell treatment he received to overcome heart failure.

Read the rest here:
Stem Cell Treatment for Heart Failure – Video

Cardiac Stem Cell Transplant – Video


27-01-2012 21:30 TORONTO – Doctors have performed Ontario’s first cardiac stem cell transplant using cells from the patient’s own bone marrow.

More here:
Cardiac Stem Cell Transplant – Video

Cardiac Stem Cell Transplant – Video


27-01-2012 21:30 TORONTO – Doctors have performed Ontario’s first cardiac stem cell transplant using cells from the patient’s own bone marrow.

Here is the original post:
Cardiac Stem Cell Transplant – Video

VistaGen's Cardiac OrganDots(TM) Produced for Drug Rescue – Video


08-11-2011 12:57 Human pluripotent stem cell derived cardiomyocytes (cardiac tissue) grown on an “air-liquid-interface” culture system to produce “microheart” OrganDots™. These OrganDots™, a core technology supporting VistaGen’s drug rescue programs, are used to evaluate the positive (“efficacy”) and negative (“toxicity”) of drugs and drug candidates on the electrical functions and beating rates of the microhearts.

Link:
VistaGen’s Cardiac OrganDots(TM) Produced for Drug Rescue – Video

VistaGen’s Cardiac OrganDots(TM) Produced for Drug Rescue – Video


08-11-2011 12:57 Human pluripotent stem cell derived cardiomyocytes (cardiac tissue) grown on an “air-liquid-interface” culture system to produce “microheart” OrganDots™. These OrganDots™, a core technology supporting VistaGen’s drug rescue programs, are used to evaluate the positive (“efficacy”) and negative (“toxicity”) of drugs and drug candidates on the electrical functions and beating rates of the microhearts.

Excerpt from:
VistaGen’s Cardiac OrganDots(TM) Produced for Drug Rescue – Video

Adult Stem Cells Used To Rebuild Heart Tissue Video.mp4 – Video


21-06-2010 19:24 This video goes into Severe Heart Disease and shows how adult stem cells can improve the clinical condition.. More information can be found at http://www.vescell.com

View post:
Adult Stem Cells Used To Rebuild Heart Tissue Video.mp4 – Video

Adult Stem Cells Used To Rebuild Heart Tissue Video.mp4 – Video


21-06-2010 19:24 This video goes into Severe Heart Disease and shows how adult stem cells can improve the clinical condition.. More information can be found at http://www.vescell.com

Original post:
Adult Stem Cells Used To Rebuild Heart Tissue Video.mp4 – Video

Power Cell Lifting (Scaffold Lifting) Operation (2) – PNC International – Video


22-12-2011 18:50 Power Cell Lifting (Scaffold Lifting) is New Lifting Technique which injects Multiple Threads for Strong Lifting Effect and for Enhancing Cell Engraftment to the treatment areas. The thread is made of PDO Material, which is safe enough to have been used for cardiac surgery.

Read more here:
Power Cell Lifting (Scaffold Lifting) Operation (2) – PNC International – Video

Prometheus and I: building new body parts from stem cells (15 Nov 2011) – Video


18-11-2011 05:34 UCL Lunch Hour Lecture: Prometheus and I: building new body parts from stem cells Professor Martin Birchall (UCL Ear Institute) Prometheus created life from clay, and within many biologists and surgeons there is a primal desire to do the same from the materials at hand, in an effort to stave off death and disease. Organ transplantation has been one Promethean solution, but a lack of donor organs, ethical and other issues limits the stretch of this technology.

See more here:
Prometheus and I: building new body parts from stem cells (15 Nov 2011) – Video

bboy force the stem cell miracle man part 2 of 2 witness the magic – Video


24-12-2011 14:49 bboy force back in action AKA captain boogiedown lives!! the DOUBLE BLIND STUDY of adult stem cell research extracted from bone marrow has worked a miracle! Witness the miracle. see part 1

Read the rest here:
bboy force the stem cell miracle man part 2 of 2 witness the magic – Video

Power Cell Lifting (Scaffold Lifting) Injection Technique – PNC International – Video


22-12-2011 20:12 Power Cell Lifting (Scaffold Lifting) is New Lifting Technique which injects Multiple Threads for Strong Lifting Effect and for Enhancing Cell Engraftment to the treatment areas. The thread is made of PDO Material, which is safe enough to have been used for cardiac surgery.

Read more:
Power Cell Lifting (Scaffold Lifting) Injection Technique – PNC International – Video

Power Cell Lifting (Scaffold Lifting) Operation (1) – PNC International – Video


22-12-2011 18:59 Power Cell Lifting (Scaffold Lifting) is New Lifting Technique which injects Multiple Threads for Strong Lifting Effect and for Enhancing Cell Engraftment to the treatment areas. The thread is made of PDO Material, which is safe enough to have been used for cardiac surgery. Its Differentiated Advantages are, ?

Read more here:
Power Cell Lifting (Scaffold Lifting) Operation (1) – PNC International – Video

bboy force the stem cell miracle man part 2 of 2 witness the magic – Video


24-12-2011 14:49 bboy force back in action AKA captain boogiedown lives!! the DOUBLE BLIND STUDY of adult stem cell research extracted from bone marrow has worked a miracle! Witness the miracle. see part 1

Excerpt from:
bboy force the stem cell miracle man part 2 of 2 witness the magic – Video

Power Cell Lifting (Scaffold Lifting) Injection Technique – PNC International – Video


22-12-2011 20:12 Power Cell Lifting (Scaffold Lifting) is New Lifting Technique which injects Multiple Threads for Strong Lifting Effect and for Enhancing Cell Engraftment to the treatment areas.

More here:
Power Cell Lifting (Scaffold Lifting) Injection Technique – PNC International – Video

Power Cell Lifting (Scaffold Lifting) Operation (1) – PNC International – Video


22-12-2011 18:59 Power Cell Lifting (Scaffold Lifting) is New Lifting Technique which injects Multiple Threads for Strong Lifting Effect and for Enhancing Cell Engraftment to the treatment areas. The thread is made of PDO Material, which is safe enough to have been used for cardiac surgery. Its Differentiated Advantages are, ?

See more here:
Power Cell Lifting (Scaffold Lifting) Operation (1) – PNC International – Video

Power Cell Lifting (Scaffold Lifting) Operation (2) – PNC International – Video


22-12-2011 18:50 Power Cell Lifting (Scaffold Lifting) is New Lifting Technique which injects Multiple Threads for Strong Lifting Effect and for Enhancing Cell Engraftment to the treatment areas. The thread is made of PDO Material, which is safe enough to have been used for cardiac surgery. Its Differentiated Advantages are, ?

Go here to see the original:
Power Cell Lifting (Scaffold Lifting) Operation (2) – PNC International – Video

Prometheus and I: building new body parts from stem cells (15 Nov 2011) – Video


18-11-2011 05:34 UCL Lunch Hour Lecture: Prometheus and I: building new body parts from stem cells Professor Martin Birchall (UCL Ear Institute) Prometheus created life from clay, and within many biologists and surgeons there is a primal desire to do the same from the materials at hand, in an effort to stave off death and disease.

See the rest here:
Prometheus and I: building new body parts from stem cells (15 Nov 2011) – Video

Stem Cell Clinical Trial for Heart Failure: Eduardo Marban – CIRM Spotlight on Disease – Video


CIRM has funded a $5.5 million Disease Team to develop a follow on clinical trial that uses a patient’s own heart stem cells to regenerate scarred tissue damaged by a heart attack.

See the original post here:
Stem Cell Clinical Trial for Heart Failure: Eduardo Marban – CIRM Spotlight on Disease – Video

Coast To Coast AM: Regenerative Medicine / Dulce Base 11-15-2011 Download Link – Video


DOWNLOAD LINK: adf.ly (CLICK ON “REGULAR DOWNLOAD” BUTTON FOR FREE DOWNLOAD) FOLLOW ON TWITTER: twitter.com SUBSCRIBE TO MY YOUTUBE CHANNEL: http://www.youtube.com REGISTER FOR HOTFILE ACCOUNT: hotfile.com REGISTER FOR FILESERVE ACCOUNT: http://www.fileserve.com http://www.coasttocoastam.com Date: 11-15-11 Host: George Noory Guests: Anthony F. Sanchez, Christian Wilde In the first half, researcher Christian Wilde talked about the emerging field of regenerative medicine, and how scientists are actually building replacement body parts with stem cells. He announced that Dr.

The rest is here:
Coast To Coast AM: Regenerative Medicine / Dulce Base 11-15-2011 Download Link – Video

C2CAM – 2011.11.15 – Dulce Base – Regenerative Medicine – Info – Video


Coast to Coast AM Regenerative Medicine/ Dulce Base Date: 11-15-11 Host: George Noory Guests: Anthony F.

Read more:
C2CAM – 2011.11.15 – Dulce Base – Regenerative Medicine – Info – Video

C2CAM – 2011.11.15 – Dulce Base – Regenerative Medicine – Video


Coast to Coast AM Regenerative Medicine/ Dulce Base Date: 11-15-11 Host: George Noory Guests: Anthony F. Sanchez, Christian Wilde News segment guests: Nick Begich, Dr. Robert Manning [Quick Info] First Half: Researcher Christian Wilde talks about the emerging field of regenerative medicine; scientists are actually building replacement body parts with stem cells

Continued here:
C2CAM – 2011.11.15 – Dulce Base – Regenerative Medicine – Video

Latest Update on Stem Cell Research at UW – Dr. Timothy Kamp – Video


orlive.uwhealth.org Researcher, Dr. Timothy Kamp, discusses the depth and breadth of stem cell research at the UW. Dr

Follow this link:
Latest Update on Stem Cell Research at UW – Dr. Timothy Kamp – Video

Archives